Brainstem Circuit Modulation Therapy is a novel therapeutic approach targeting the brainstem circuit dysfunction that underlies the core clinical features of Progressive Supranuclear Palsy (PSP). This therapy addresses the dysfunction of basal ganglia output nuclei and brainstem gaze control centers that produce the characteristic falls, vertical gaze palsy, and axial rigidity in PSP.
PSP is characterized by progressive dysfunction in multiple brainstem circuits:
- Basal ganglia output dysfunction — Excessive inhibitory output from GPi/SNr to thalamus and brainstem
- Oculomotor circuit failure — Degeneration of the interstitial nucleus of Cajal, nucleus of Darkschewitsch, and superior colliculus
- Pedunculopontine nucleus (PPN) degeneration — Contributing to gait freezing and postural instability
- Reticular formation dysfunction — Contributing to axial rigidity and dysphagia
Key clinical features addressed:
- Falls due to parkinsonism and axial rigidity
- Vertical supranuclear gaze palsy (VSGP)
- Dysphagia and dysarthria
- Gait freezing and postural instability
- Cognitive dysexecutive syndrome
This therapy employs multiple complementary mechanisms:
- Deep brain stimulation optimization — Advanced DBS targeting PPN and GPi with adaptive closed-loop protocols
- GABAergic circuit enhancement — Small molecule enhancement of inhibitory GABAergic signaling in basal ganglia output
- Pedunculopontine nucleus targeting — PPN stimulation or pharmacologic modulation to restore gait and postural control
- Serotonergic modulation — Target brainstem raphe nuclei to address ocular motility and mood dysfunction
| Dimension |
Score |
Rationale |
| Novelty |
7 |
Builds on established DBS field with novel adaptive protocols |
| Mechanistic Rationale |
8 |
Strong evidence for brainstem circuit dysfunction in PSP pathophysiology |
| Root-Cause Coverage |
6 |
Addresses circuit dysfunction, not primary tau pathology |
| Delivery Feasibility |
8 |
DBS infrastructure exists; pharmacologic approaches readily deliverable |
| Safety Plausibility |
7 |
Established safety profiles for DBS and GABAergic drugs |
| Combinability |
9 |
Highly synergistic with 4R-tau targeting, neuroinflammation modulation |
| Biomarker Availability |
7 |
Video-oculography for gaze tracking, wearable sensors for gait analysis |
| De-risking Path |
8 |
Can leverage existing DBS infrastructure and known drug safety profiles |
| Multi-disease Potential |
8 |
Applicable to MSA, Parkinson's disease, and other movement disorders |
| Patient Impact |
9 |
Addresses disabling symptoms with high unmet need |
Total Score: 75/100
| Disease |
Coverage Score |
Rationale |
| Alzheimer's Disease |
4 |
May benefit from brainstem circuit modulation for gait/balance |
| Parkinson's Disease |
8 |
Well-established target for DBS and pharmacologic modulation |
| ALS |
4 |
Brainstem involvement in later stages |
| FTD |
5 |
May benefit from circuit modulation for executive dysfunction |
| PSP |
10 |
Primary indication; core mechanism |
| MSA |
8 |
Cerebellar and brainstem circuit dysfunction in MSA-C |
| Aging |
5 |
May address age-related gait and balance decline |
- Validate circuit dysfunction biomarkers in PSP patients
- Test pharmacologic candidates in relevant animal models
- Develop adaptive DBS protocols for PSP-specific patterns
- GLP toxicology for lead compounds
- Surgical safety optimization for PSP patients (higher fall risk)
- Assess cognitive effects of circuit modulation
- Patient selection: Early-to-mid stage PSP patients
- Clinical endpoints: PSP-RS score, falls frequency, swallowing function
- Biomarker endpoints: Video-oculography, quantitative gait analysis
- Cognitive effects: Careful monitoring for DBS-induced cognitive decline
- Surgical risk: Optimize lead placement accuracy with advanced imaging
- Dysphagia: Monitor for aspiration risk during treatment
Brainstem Circuit Modulation Therapy is highly synergistic with:
- + 4R-Tau Targeting Therapy — Preserve remaining neurons while supporting circuit function
- + Neuroinflammation modulation — Reduce inflammatory contribution to circuit dysfunction
- + Antioxidant therapy — Protect brainstem nuclei from oxidative damage
- + Physical/rehabilitation therapy — Maximize benefit of preserved circuit function
- PET studies show reduced glucose metabolism in PPN in PSP
- DTI reveals white matter tract degeneration connecting brainstem nuclei
- Functional MRI shows altered connectivity in basal ganglia-thalamocortical circuits
- Neurodegeneration in PPN correlates with gait impairment severity
- Cholinergic neuron loss in PPN documented in PSP cases
- Neurofibrillary tangle burden in brainstem nuclei correlates with clinical features
- PPN-DBS shows modest benefit in PSP gait and postural stability
- GABAergic agents provide temporary symptom relief in some patients
- Adaptive DBS protocols under investigation show promise
- Complete preclinical validation of lead pharmacologic candidates
- Initiate multi-center natural history study with circuit biomarkers
- Develop adaptive DBS protocols for PSP
- First-in-human study of lead compound
- Pilot DBS trial with adaptive protocols
- Establish validated circuit dysfunction biomarkers
- Pivotal trial for registration
- Develop combination therapy with tau-targeting approaches
- Expand to other neurodegenerative conditions
- Identify lead candidates: Prioritize GABAergic and serotonergic compounds with brainstem penetration
- Engage DBS centers: Partner with movement disorder centers experienced in PSP DBS
- Biomarker development: Standardize video-oculography and quantitative gait protocols
- Regulatory pathway: Discuss accelerated approval with FDA based on high unmet need
- Patient registry: Establish PSP patient registry with longitudinal circuit function data